Northwire Canada EditionFriday, August 14, 2026
Sign inSubscribe
Northwire
⌕
NUAG 9.45 +1.0% KRN 0.300 +11.1% EON 0.020 −nan% EMO 0.420 −1.2% WGF 0.150 −3.2% SXL 0.070 +16.7% LITH 0.500 −15.2% CLZ 0.045 +0.0% HMR 0.500 −2.0% NAU 1.85 +2.8% PPTA 34.95 +1.3% PA 0.155 −3.1% FAIR 0.055 +0.0% EMR 0.080 +23.1% AEF 0.140 +0.0% TIGR 0.770 +4.0% NUAG 9.45 +1.0% KRN 0.300 +11.1% EON 0.020 −nan% EMO 0.420 −1.2% WGF 0.150 −3.2% SXL 0.070 +16.7% LITH 0.500 −15.2% CLZ 0.045 +0.0% HMR 0.500 −2.0% NAU 1.85 +2.8% PPTA 34.95 +1.3% PA 0.155 −3.1% FAIR 0.055 +0.0% EMR 0.080 +23.1% AEF 0.140 +0.0% TIGR 0.770 +4.0%
Financings

Molecule Holdings Inc. Provides Corporate Update

By The Northwire Desk — AI Analysis Oct 27, 2025 · 20:00 MLCL · 0.005 Molecule Holdings Inc.
MLCL · Price

Executive Summary

  • Molecule Holdings completed an amendment transaction converting $2.905 M of 8% unsecured convertible debentures (≈92.5% of the outstanding principal) into 189,060,500 common shares and 75,624,200 warrants, plus accrued interest and a 10% premium (~$3.73 M total).
  • The company remains under a Failure‑to‑File Cease Trade Order (FFCTO) issued by the OSC; it has secured three partial revocation orders to permit the amendment transaction and to seek additional financing.
  • No new financing has been completed to date due to market conditions and FFCTO constraints, and the firm cannot guarantee that it will raise capital or have the FFCTO fully lifted.

Key Details

  • FFCTO Background: Issued March 5 2024 for failure to file 2023 annual financial statements and related MD&A; interim filings were also late due to a dispute with a former CFO‑type consultant.
  • Interim Management Changes: André Audet (Chairman & Co‑Founder) appointed Interim CFO; two independent consultants engaged for accounting, bookkeeping, and financial services.
  • Partial Revocation Orders: Received three orders from the OSC allowing:
  • Amendment & conversion of unsecured debentures, and
  • Pursuit of a financing to fund outstanding payables (including auditor fees).
  • Amendment Transaction Details (Nov 28 2024 & Jun 2 2025):
  • Principal amount converted: $2,905,000 (≈92.5% of total debentures).
  • Total consideration after interest and 10% premium: ≈$3,730,000.
  • Shares issued: 189,060,500 common shares.
  • Warrants issued: 75,624,200 warrants to purchase common shares.
  • Financing Status: No financing secured yet; market conditions and FFCTO restrictions cited as barriers. The company continues to engage auditors for outstanding filings and will seek financing on “appropriate terms.”
  • Future Outlook & Risks:
  • FFCTO remains until all Outstanding Filings are filed and the order is fully revoked per National Policy 11‑207.
  • No assurance that the company can complete a financing or lift the FFCTO.
  • Business Update: Ongoing strategic/operational changes aimed at efficiency; seeking strong partners to expand core cannabis‑beverage business and resolve liabilities.

Notable Quotes

“Completing the Amendment Transaction was an important step in the restructuring of the Company’s balance sheet to provide the Company with greater flexibility and be more attractive for investment.” – André Audet, Chairman & Co‑Founder

Materiality Assessment: Material – Neutral (significant capital structure change and regulatory status update, but no earnings or operational performance disclosed).

Read the original news release →